Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ilginatinib maleate (NS-018 maleate) 是一种可口服的 JAK2强效抑制剂,IC50值为 0.72 nM,对其选择性是对 JAK1、JAK3和 Tyk2 的 46、54 和 22 倍,IC50分别为 33、39 和 22 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 745 | 现货 | ||
2 mg | ¥ 1,150 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 3,150 | 现货 | ||
25 mg | ¥ 4,970 | 现货 | ||
50 mg | ¥ 6,880 | 现货 | ||
100 mg | ¥ 9,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,280 | 现货 |
产品描述 | Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2. |
靶点活性 | JAK2:0.72 nM, JAK1:33 nM, TYK2:22 nM, JAK3:39 nM |
体外活性 | Ilginatinib maleate(NS-018 maleate) is highly active against JAK2 with a 50% inhibition (IC(50)) of <1 n, and had 30-50-fold greater selectivity for JAK2 over other JAK-family kinases, such as JAK1, JAK3 and tyrosine kinase 2.?In addition to JAK2, NS-018 inhibited Src-family kinases.?NS-018 showed potent antiproliferative activity against cell lines expressing a constitutively activated JAK2 (the JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene;?IC(50)=11-120 n), but showed only minimal cytotoxicity against most other hematopoietic cell lines without a constitutively activated JAK2[1]. |
体内活性 | Ilginatinib maleate(NS-018 maleate) preferentially suppressed in vitro erythropoietin-independent endogenous colony formation from polycythemia vera patients.?NS-018 also markedly reduced splenomegaly and prolonged the survival of mice inoculated with Ba/F3 cells harboring JAK2V617F.?In addition, NS-018 significantly reduced leukocytosis, hepatosplenomegaly and extramedullary hematopoiesis, improved nutritional status, and prolonged survival in JAK2V617F transgenic mice.?suggest that NS-018 will be a promising candidate for the treatment of MPNs[1]. |
别名 | NS-018 maleate |
分子量 | 505.5 |
分子式 | C25H24FN7O4 |
CAS No. | 1354799-87-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (59.35 mM)
H2O: < 0.1 mg/mL (insoluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9782 mL | 9.8912 mL | 19.7824 mL | 49.456 mL |
5 mM | 0.3956 mL | 1.9782 mL | 3.9565 mL | 9.8912 mL | |
10 mM | 0.1978 mL | 0.9891 mL | 1.9782 mL | 4.9456 mL | |
20 mM | 0.0989 mL | 0.4946 mL | 0.9891 mL | 2.4728 mL | |
50 mM | 0.0396 mL | 0.1978 mL | 0.3956 mL | 0.9891 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ilginatinib maleate 1354799-87-3 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK Inhibitor JAK3 NS 018 inhibit JAK2 NS018 Maleate Ilginatinib NS-018 Maleate bioavailable NS018 orally NS-018 JAK1 Janus kinase NS-018 maleate Tyk2 NS 018 Maleate Ilginatinib Maleate inhibitor